Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constan...
Apathy drug candidate completed Ph 1 in elderly adults Positive PK, safety and tolerability data con...
Redeye updates on Evolution following Q4-results which were in with our forecasts.
Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
Diagonal Bio är ett bioteknikbolag som utvecklar och säljer en analysplattform för identifiering av ...
Redeye comments on Enea’s Q4 2024 report, where sales met Redeye Research estimates (RRe) in Enea’s ...
Sales -3%, adj. EBITA -8% vs. cons, -6% org. growth Consensus to lower '24e-'25e EBITA by 3-5% Share...
We lower adjusted EBITA by 5% for 2025E-27E following the Q4 report.
Nosa Plugs AB (”Nosa Plugs” eller ”Bolaget”) meddelade den 29 januari år 2025 att Bolaget har knutit...
Redeye provides a preview of SSH's Q4 results set to be released on February 14.
On January 29th, Eevia Health Plc (publ) (“Eevia”) announced ten new sales orders for products total...
A good Q4 coming up with 9% revenue and 15% EPS growth 2025 guidance likely to show accelerating gro...
XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
Q4 not likely to be a game-changer New design win with Dell opens large new segment Ambition of 50-6...
